ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 34 of 48
УЖМБС 2018, 3(2): 194–199
Medicine. Reviews

Target Preparations in Ovarian Cancer Therapy

Neffa M. Yu.

World science does not stop attempts to improve the effectiveness of malignant ovary neoplasms treatment, taking into account the fact that this pathology mortality rate takes the steady first place in cancer gynecology. The search for screening and early diagnosis algorithms, as well as the surgical improvement in this type of tumor treatment continues. Thanks to molecular biology innovations, there are significant advances in understanding the etiology and pathogenesis of the disease. In this regard, the main interest of researchers is in studying and developing new drugs that can not only improve the effectiveness of treatment, but also do not reduce the life quality of this category of patients. It should be noted that the life quality indicator in modern oncology is in line with the survival rate and is one of the main criteria for assessing the treatment effectiveness. Over the past half century, there have occurred a number of revolutionary changes in drug therapy of one of the most insidious malignant neoplasms in the female genecology. The main cornerstones in the progression of ovarian cancer chemotherapy are related to the introduction of platinum series drugs to the routine practice, and then taxol. Today, there is an active search for targets for applying new generation drugs, the so-called target drugs, which damage tumor structures directly. The article summarizes the latest world experience of using various types of targeted drugs in ovarian cancer treatment. The author suggests a detailed analysis of several major recent world-wide randomized clinical studies of using various groups targeting agents in the combined and integrated treating common forms of ovarian cancer. The article clearly outlines the advantages and disadvantages of using each studied drugs on the examples of the results obtained during clinical application. A comparative analysis of their application is presented in monorail, as well as in combinations with well-known and widely used drugs for ovarian cancer chemotherapy. The author notes that the most effective and of the studied targeted drugs is bevacizumab. The article also points out that it has been successfully used for several years in ovarian cancer treatment. The present review does not pretend to fully reflect the situation in preclinical and clinical trials of antitumor drugs for ovarian cancer. All the drugs are united by the presence of a specific molecular target in the tumor cell. No one doubts that the future of clinical oncology is associated with a personalized approach and depends on the definition of molecular genetic characteristics of the tumor. The first steps in this direction are taken in ovarian cancer treatment. At present, several works based on a large number of observations have been published in the world. They identify 6 molecular subtypes of ovarian cancer. All of the above mentioned suggests that understanding of molecular genetics mechanisms and the identification of targets are increasingly necessary in routine clinical practice for the personalized selection of therapy and the determination of its effectiveness, which, in turn, becomes the main trend in ovarian cancer treatment improving.

Keywords: ovarian cancer, clinical studies, target therapy, bevacizumab

Full text: PDF (Rus) 213K

  1. Aghajanian C, Finkler N, Rutherford T, Smith DA, Yi J, Parmar H, Nycum LR, Sovak MA. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarien (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Clin Oncol. 2012; 29: LBA5007.
  2. Asadollahi R, Hyde C, Zhong X. Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol Oncol. 2010; 118 (1): 81-7.
  3. Burger R, Brady M, Bookman M, Walker JL, Homesley HD, Fowler J. Phase III trial of bevacizumab (bev) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol. 2012; 28. LBA 1.
  4. Bast R, Henessy B, Mills G. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2014; 9 (6): 415-28.
  5. Cho K. Ovarian cancer update: lessons from morphology, molecules and mice. Arch Pathol Lab Med. 2013; 133 (1): 1775-81.
  6. Cancer genome atlas research network. Integrated genomic analyses of ovarian carcinoma. Nature. 2016; 474 (7252): 609-15.
  7. Cannistra S. Cancer of ovarian. N Engl J Med. 2014; 351: 2519-29.
  8. Del Camp J, Kurzeder C, Berton-Riguad D, et al. Progression-free survival by GCIG criteria: analysis of the secondary endpoint of the AGO-OVAR16 trial. Int J Gynecol Cancer. 2013; 23: 126.
  9. Du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT-INTERGROUP phase III trial of standart frontline chemotherapy+/- nintedanib for advanced ovarian cancer. Int J Gunecol Cancer. 2013: 23: 7.
  10. Harrias M, Gore M. Chemotherapy for epitelial ovarian cancer – treatment at first diagnosis. The Lancet Oncol. 2002; 3 (9): 529-36.
  11. Gelnon K, Hirte H, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple negative breast cancer. J Clin Oncol. 2014; 28 (5): 3002.
  12. Helland A, Anglesio M, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. Plose One. 2011; 6: 18064.
  13. Keith B, Simon M. Tumor angiogenesis. The Molecular Basis of Cancer. Ed. by J. Mendelsohn. 3rd ed. Elseiver, 2015. p. 241-51.
  14. Banerjee S, Kaye B. New strategies in the treatment of ovarien cancer: current clinical perspective and future potential. Clin Cancer Res. 2013: 19: 961-8.
  15. Konecny G, Wang C, Winterhoff B, Winterhoff B, Dering J, Ginther C, Chen H-W. Prognostic relevance of gene signatures in high-grade serous avarian carcinoma. J Clin Oncol. 2015; 31: 5510.
  16. Kaye B, Kaufman S, Lubinski J, et al. Phase II study of the oral PARP inhibitor olaparib (AZD2281) vs liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations. Ann Oncol. 2014; 21: 9710.
  17. Kalli K, Oberg A, Keeney G, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epitelial ovarian cancer. Gynecol Oncol. 2012; 108: 3: 619-26.
  18. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366 (15): 1382-92.
  19. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation. J Clin Oncol. 2013; 31: 5505.
  20. Matulonis U, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, et al. Cediranib an oral inhibitor of vascular endothelial growth factors receptor kinases is an active drug in recurrent epithelial ovarian, fallopian tube and peritoneal cancer. J Clin Oncol. 2015; 27 (33): 5601-6.
  21. Modesitt S, Sill M, Hoffman J, Bender DP; Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2014; 109 (2): 182-6.
  22. Manetta A, Blessing J, Look K. A phase II study of fazarabine in patients with advanced ovarian cancer. Am J Clin Oncol. 2015; 18 (2): 156-7.
  23. Naumann R, Coleman R, Burger R, et al. A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in subjects with platinum-resistant ovarian cancer. J Clin Oncol. 2016; 29 (15): 5045.
  24. Pinilla-Dominguez P, Ricbardson P, Robertsom J, Adam J. NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced avarian cancer. The Lancet Oncol. 2013; 14: 689-90.
  25. Press J, de Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, et al. Ovarian carcinoma with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2014; 8: 17.
  26. Perrent T, Swart A, Pfisterer J, et al. ICON7: A phase III randomized gynecologoc cancer intergroup trial of concurrent bevacizumab by maintenance bevacizumab versus chemotherapy alone in women with newly diagnosed epithelial ovarian cancer (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol. 2013; 21: LBA4.
  27. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. AURELIA: a randomized phase III trial evaluating bevacizumab plus chemotherapy for platinumresistant recurrent ovarian cancer. J Clin Oncol. 2012; 30: LBA5002.
  28. Weil M, Chen A. PARP inhibitor treatment in ovarian breast cancer. Curr Probl Cancer. 2014; 35 (1): 7-50.